Veterans Call for FDA Committee Meeting on NurOwn’s Benefits

Veterans Call for FDA Committee Meeting on NurOwn’s Benefits

Veterans with amyotrophic lateral sclerosis (ALS) are calling for the U.S. Food and Drug Administration (FDA) to hold a public advisory committee meeting to discuss the benefits of NurOwn — an investigational cell-based therapy that military service members say has slowed their disease. The request follows the regulatory…

Midweek Meditations for ALS Patients and Other Mindful News

I’m excited to share good news about the growing access by ALS patients to the benefits of mindfulness and meditation. As readers of this column likely know, I’ve been on a quest to increase awareness in the ALS community about these wonderful mind-body practices. Being mindful…

Results of Phase 3 Trial of TUDCA in Slowing ALS Likely Next Year

An ongoing Phase 3 clinical trial in Europe is testing whether tauroursodeoxycholic acid, added to standard therapy, can slow disease progression and extend survival among people with amyotrophic lateral sclerosis (ALS). The oral compound, also known as TUDCA, is one of the two ingredients in Relyvrio (sodium phenylbutyrate…